window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

radiopharmaceuticals

  • Digital & Data,Drug Discovery & Development,Research & Development,Therapeutic Areas

    Nucs AI taps Segmed’s 150 million imaging studies to strengthen oncology AI

    Nucs AI has partnered with healthcare data specialist Segmed to [...]

    July 15, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    First patients dosed in Phase 1 trial of DLL3-targeted radiopharmaceutical for small cell lung cancer

    The first patients have been dosed with MP0712, a DLL3-targeted [...]

    July 3, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    FDA backs Telix Phase 3 ProstACT trial expansion into US

    Telix Pharmaceuticals has received FDA agreement on the protocol and [...]

    July 3, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Phase 3 data support PSMA-targeted radiopharmaceutical combination approach in advanced prostate cancer

    Phase 3 data presented at ASCO 2026 suggest a PSMA-targeted [...]

    June 6, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research

    Oncodesign Services has expanded its collaboration with French research institute [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Regeneron enters radiopharmaceuticals through multi-programme collaboration with Telix in oncology expansion

    Regeneron Pharmaceuticals has entered the radiopharmaceuticals field through a multi-programme [...]

    May 5, 2026
  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    UK nuclear materials to power new precision cancer therapies

    The UK is launching a major programme to convert used [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    XenoSTART and Minerva Imaging expand collaboration on radiopharmaceutical drug development

    XenoSTART and Minerva Imaging have expanded their long-standing partnership to [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA and Telix agree resubmission plan for Pixclara glioma imaging agent

    Telix Pharmaceuticals has reached agreement with the US Food and [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    VIVES Partners joins Nuclidium AG’s €84M Series B Financing to advance copper-based radiopharmaceuticals

    VIVES Partners, managing company of VIVES Funds, has joined a [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top